Immunogenicity of a spike protein subunit-based COVID-19 vaccine with broad protection against various SARS-CoV-2 variants in animal studies
SARS-CoV-2 pandemic has profound impacts on human life and global economy since the outbreak in 2019. With the new variants continue to emerge with greater immune escaping capability, the protectivity of the available vaccines is compromised. Therefore, development a vaccine that is capable of induc...
Gespeichert in:
| Veröffentlicht in: | PloS one 2023-03, Vol.18 (3), p.e0283473-e0283473 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0283473 |
|---|---|
| container_issue | 3 |
| container_start_page | e0283473 |
| container_title | PloS one |
| container_volume | 18 |
| creator | Yang, Ming-Chen Wang, Chun-Chung Tang, Wei-Chien Chen, Kuan-Ming Chen, Chu-Ying Lin, Hsiao-Han Hsieh, Yin-Cheng Wang, Nan-Hsuan Kuo, Yin-Chieh Chu, Ping-Tzu Tung, Hsin-Yi Wu, Yi-Chen Sun, Juo-Ling Liu, Sheng-Yu Li, Wan-Fen Lee, Wei-Han Lai, Jiann-Shiun Chang, Michael Lai, Ming-Tain |
| description | SARS-CoV-2 pandemic has profound impacts on human life and global economy since the outbreak in 2019. With the new variants continue to emerge with greater immune escaping capability, the protectivity of the available vaccines is compromised. Therefore, development a vaccine that is capable of inducing immunity against variants including omicron strains is in urgent need. In this study, we developed a protein-based vaccine BCVax that is consisted of antigen delta strain spike protein and QS21-based adjuvant AB801 in nanoparticle immune stimulation complex format (AB801-ISCOM). Results from animal studies showed that high level of anti-S protein IgG was induced after two doses of BCVax and the IgG was capable of neutralizing multiple variants of pseudovirus including omicron BA.1 or BA.2 strains. In addition, strong Th1 response was stimulated after BCVax immunization. Furthermore, BCvax with AB801-ISCOM as the adjuvant showed significant stronger immunity compared with the vaccine using aluminum hydroxide plus CpG 1018 as the adjuvant. BCVax was also evaluated as a booster after two prior vaccinations, the IgG titers and pseudovirus neutralization activities against BA.2 or BA.4/BA.5 were further enhanced suggesting BCVax is a promising candidate as booster. Taken together, the pre-clinical data warrant BCVax for further development in clinic. |
| doi_str_mv | 10.1371/journal.pone.0283473 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2790305497</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A742879681</galeid><doaj_id>oai_doaj_org_article_6fb17c9ac64c44429bdf1cbbdafd9f89</doaj_id><sourcerecordid>A742879681</sourcerecordid><originalsourceid>FETCH-LOGICAL-c623t-a621fc1eab287fb7a08edc041273b390984c9d3eec8111669917b282a0adf6e03</originalsourceid><addsrcrecordid>eNqNk11v0zAUhiMEYmPwDxBYQkJwkeKP1ImvUFW-Kk2qtEJvrRPHST1Su4udwf4DPxp3zaYG7QLlwtHx874-Pj4nSV4SPCEsJx8uXd9ZaCc7Z_UE04JlOXuUnBLBaMopZo-P_k-SZ95fYjxlBedPkxPGBScF5afJn8V221vXaGuUCTfI1QiQ35mfGu06F7SxyPdlb01IS_C6QvPlevEpJQJdg1LGavTLhA0qOwfVQaGCcRZBA8b6EKnOuN6j1exilc7dOqW3IbDBo-gN1myhRT70ldH-efKkhtbrF8N6lvz48vn7_Ft6vvy6mM_OU8UpCylwSmpFNJS0yOsyB1zoSuGM0JyVTGBRZEpUTGtVEEI4F4LkEaWAoaq5xuwseX3w3bXOy6GQXtJcYIanmcgjsTgQlYNLuetilt2NdGDkbcB1jYQuGNVqyeuS5EqA4pnKsoyKsqqJKssK6krUhYheH4fT-nIbE9U2dNCOTMc71mxk464lwZgVDO-zeTc4dO6q1z7IrfFKty1YHYu7Tzy2xLQoaETf_IM-fL2BaiDewNjaxYPV3lTO8ixWVfCCRGryABW_Sm-Nim1XmxgfCd6PBJEJ-ndooPdeLlYX_88u12P27RG70dCGjXdtv-80PwazA6g6532n6_sqEyz3U3NXDbmfGjlMTZS9On6he9HdmLC_XugTjQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2790305497</pqid></control><display><type>article</type><title>Immunogenicity of a spike protein subunit-based COVID-19 vaccine with broad protection against various SARS-CoV-2 variants in animal studies</title><source>Public Library of Science (PLoS) Journals Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Yang, Ming-Chen ; Wang, Chun-Chung ; Tang, Wei-Chien ; Chen, Kuan-Ming ; Chen, Chu-Ying ; Lin, Hsiao-Han ; Hsieh, Yin-Cheng ; Wang, Nan-Hsuan ; Kuo, Yin-Chieh ; Chu, Ping-Tzu ; Tung, Hsin-Yi ; Wu, Yi-Chen ; Sun, Juo-Ling ; Liu, Sheng-Yu ; Li, Wan-Fen ; Lee, Wei-Han ; Lai, Jiann-Shiun ; Chang, Michael ; Lai, Ming-Tain</creator><contributor>Ito, Etsuro</contributor><creatorcontrib>Yang, Ming-Chen ; Wang, Chun-Chung ; Tang, Wei-Chien ; Chen, Kuan-Ming ; Chen, Chu-Ying ; Lin, Hsiao-Han ; Hsieh, Yin-Cheng ; Wang, Nan-Hsuan ; Kuo, Yin-Chieh ; Chu, Ping-Tzu ; Tung, Hsin-Yi ; Wu, Yi-Chen ; Sun, Juo-Ling ; Liu, Sheng-Yu ; Li, Wan-Fen ; Lee, Wei-Han ; Lai, Jiann-Shiun ; Chang, Michael ; Lai, Ming-Tain ; Ito, Etsuro</creatorcontrib><description>SARS-CoV-2 pandemic has profound impacts on human life and global economy since the outbreak in 2019. With the new variants continue to emerge with greater immune escaping capability, the protectivity of the available vaccines is compromised. Therefore, development a vaccine that is capable of inducing immunity against variants including omicron strains is in urgent need. In this study, we developed a protein-based vaccine BCVax that is consisted of antigen delta strain spike protein and QS21-based adjuvant AB801 in nanoparticle immune stimulation complex format (AB801-ISCOM). Results from animal studies showed that high level of anti-S protein IgG was induced after two doses of BCVax and the IgG was capable of neutralizing multiple variants of pseudovirus including omicron BA.1 or BA.2 strains. In addition, strong Th1 response was stimulated after BCVax immunization. Furthermore, BCvax with AB801-ISCOM as the adjuvant showed significant stronger immunity compared with the vaccine using aluminum hydroxide plus CpG 1018 as the adjuvant. BCVax was also evaluated as a booster after two prior vaccinations, the IgG titers and pseudovirus neutralization activities against BA.2 or BA.4/BA.5 were further enhanced suggesting BCVax is a promising candidate as booster. Taken together, the pre-clinical data warrant BCVax for further development in clinic.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0283473</identifier><identifier>PMID: 36961826</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adjuvants, Immunologic ; Adjuvants, Pharmaceutic ; Aluminum ; Aluminum hydroxide ; Analysis ; Animal experimentation ; Animals ; Animals, Laboratory ; Antibodies, Neutralizing ; Antibodies, Viral ; Antigens ; Biology and Life Sciences ; Coronaviruses ; COVID-19 ; COVID-19 - prevention & control ; COVID-19 Vaccines ; Evaluation ; Global economy ; Humans ; Immunity ; Immunization ; Immunogenicity ; Immunoglobulin G ; Infections ; ISCOMS ; Lymphocytes T ; Medicine and Health Sciences ; Molecular weight ; Nanoparticles ; Neutralization ; Pandemics ; Physical Sciences ; Protein Subunits ; Proteins ; Research and Analysis Methods ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2 ; Spike Glycoprotein, Coronavirus - genetics ; Spike protein ; Vaccines ; Viral diseases</subject><ispartof>PloS one, 2023-03, Vol.18 (3), p.e0283473-e0283473</ispartof><rights>Copyright: © 2023 Yang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</rights><rights>COPYRIGHT 2023 Public Library of Science</rights><rights>2023 Yang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 Yang et al 2023 Yang et al</rights><rights>2023 Yang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c623t-a621fc1eab287fb7a08edc041273b390984c9d3eec8111669917b282a0adf6e03</citedby><cites>FETCH-LOGICAL-c623t-a621fc1eab287fb7a08edc041273b390984c9d3eec8111669917b282a0adf6e03</cites><orcidid>0000-0001-5330-6984 ; 0000-0002-9829-7943</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10038307/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10038307/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79343,79344</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36961826$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Ito, Etsuro</contributor><creatorcontrib>Yang, Ming-Chen</creatorcontrib><creatorcontrib>Wang, Chun-Chung</creatorcontrib><creatorcontrib>Tang, Wei-Chien</creatorcontrib><creatorcontrib>Chen, Kuan-Ming</creatorcontrib><creatorcontrib>Chen, Chu-Ying</creatorcontrib><creatorcontrib>Lin, Hsiao-Han</creatorcontrib><creatorcontrib>Hsieh, Yin-Cheng</creatorcontrib><creatorcontrib>Wang, Nan-Hsuan</creatorcontrib><creatorcontrib>Kuo, Yin-Chieh</creatorcontrib><creatorcontrib>Chu, Ping-Tzu</creatorcontrib><creatorcontrib>Tung, Hsin-Yi</creatorcontrib><creatorcontrib>Wu, Yi-Chen</creatorcontrib><creatorcontrib>Sun, Juo-Ling</creatorcontrib><creatorcontrib>Liu, Sheng-Yu</creatorcontrib><creatorcontrib>Li, Wan-Fen</creatorcontrib><creatorcontrib>Lee, Wei-Han</creatorcontrib><creatorcontrib>Lai, Jiann-Shiun</creatorcontrib><creatorcontrib>Chang, Michael</creatorcontrib><creatorcontrib>Lai, Ming-Tain</creatorcontrib><title>Immunogenicity of a spike protein subunit-based COVID-19 vaccine with broad protection against various SARS-CoV-2 variants in animal studies</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>SARS-CoV-2 pandemic has profound impacts on human life and global economy since the outbreak in 2019. With the new variants continue to emerge with greater immune escaping capability, the protectivity of the available vaccines is compromised. Therefore, development a vaccine that is capable of inducing immunity against variants including omicron strains is in urgent need. In this study, we developed a protein-based vaccine BCVax that is consisted of antigen delta strain spike protein and QS21-based adjuvant AB801 in nanoparticle immune stimulation complex format (AB801-ISCOM). Results from animal studies showed that high level of anti-S protein IgG was induced after two doses of BCVax and the IgG was capable of neutralizing multiple variants of pseudovirus including omicron BA.1 or BA.2 strains. In addition, strong Th1 response was stimulated after BCVax immunization. Furthermore, BCvax with AB801-ISCOM as the adjuvant showed significant stronger immunity compared with the vaccine using aluminum hydroxide plus CpG 1018 as the adjuvant. BCVax was also evaluated as a booster after two prior vaccinations, the IgG titers and pseudovirus neutralization activities against BA.2 or BA.4/BA.5 were further enhanced suggesting BCVax is a promising candidate as booster. Taken together, the pre-clinical data warrant BCVax for further development in clinic.</description><subject>Adjuvants, Immunologic</subject><subject>Adjuvants, Pharmaceutic</subject><subject>Aluminum</subject><subject>Aluminum hydroxide</subject><subject>Analysis</subject><subject>Animal experimentation</subject><subject>Animals</subject><subject>Animals, Laboratory</subject><subject>Antibodies, Neutralizing</subject><subject>Antibodies, Viral</subject><subject>Antigens</subject><subject>Biology and Life Sciences</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 Vaccines</subject><subject>Evaluation</subject><subject>Global economy</subject><subject>Humans</subject><subject>Immunity</subject><subject>Immunization</subject><subject>Immunogenicity</subject><subject>Immunoglobulin G</subject><subject>Infections</subject><subject>ISCOMS</subject><subject>Lymphocytes T</subject><subject>Medicine and Health Sciences</subject><subject>Molecular weight</subject><subject>Nanoparticles</subject><subject>Neutralization</subject><subject>Pandemics</subject><subject>Physical Sciences</subject><subject>Protein Subunits</subject><subject>Proteins</subject><subject>Research and Analysis Methods</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Spike Glycoprotein, Coronavirus - genetics</subject><subject>Spike protein</subject><subject>Vaccines</subject><subject>Viral diseases</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqNk11v0zAUhiMEYmPwDxBYQkJwkeKP1ImvUFW-Kk2qtEJvrRPHST1Su4udwf4DPxp3zaYG7QLlwtHx874-Pj4nSV4SPCEsJx8uXd9ZaCc7Z_UE04JlOXuUnBLBaMopZo-P_k-SZ95fYjxlBedPkxPGBScF5afJn8V221vXaGuUCTfI1QiQ35mfGu06F7SxyPdlb01IS_C6QvPlevEpJQJdg1LGavTLhA0qOwfVQaGCcRZBA8b6EKnOuN6j1exilc7dOqW3IbDBo-gN1myhRT70ldH-efKkhtbrF8N6lvz48vn7_Ft6vvy6mM_OU8UpCylwSmpFNJS0yOsyB1zoSuGM0JyVTGBRZEpUTGtVEEI4F4LkEaWAoaq5xuwseX3w3bXOy6GQXtJcYIanmcgjsTgQlYNLuetilt2NdGDkbcB1jYQuGNVqyeuS5EqA4pnKsoyKsqqJKssK6krUhYheH4fT-nIbE9U2dNCOTMc71mxk464lwZgVDO-zeTc4dO6q1z7IrfFKty1YHYu7Tzy2xLQoaETf_IM-fL2BaiDewNjaxYPV3lTO8ixWVfCCRGryABW_Sm-Nim1XmxgfCd6PBJEJ-ndooPdeLlYX_88u12P27RG70dCGjXdtv-80PwazA6g6532n6_sqEyz3U3NXDbmfGjlMTZS9On6he9HdmLC_XugTjQ</recordid><startdate>20230324</startdate><enddate>20230324</enddate><creator>Yang, Ming-Chen</creator><creator>Wang, Chun-Chung</creator><creator>Tang, Wei-Chien</creator><creator>Chen, Kuan-Ming</creator><creator>Chen, Chu-Ying</creator><creator>Lin, Hsiao-Han</creator><creator>Hsieh, Yin-Cheng</creator><creator>Wang, Nan-Hsuan</creator><creator>Kuo, Yin-Chieh</creator><creator>Chu, Ping-Tzu</creator><creator>Tung, Hsin-Yi</creator><creator>Wu, Yi-Chen</creator><creator>Sun, Juo-Ling</creator><creator>Liu, Sheng-Yu</creator><creator>Li, Wan-Fen</creator><creator>Lee, Wei-Han</creator><creator>Lai, Jiann-Shiun</creator><creator>Chang, Michael</creator><creator>Lai, Ming-Tain</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-5330-6984</orcidid><orcidid>https://orcid.org/0000-0002-9829-7943</orcidid></search><sort><creationdate>20230324</creationdate><title>Immunogenicity of a spike protein subunit-based COVID-19 vaccine with broad protection against various SARS-CoV-2 variants in animal studies</title><author>Yang, Ming-Chen ; Wang, Chun-Chung ; Tang, Wei-Chien ; Chen, Kuan-Ming ; Chen, Chu-Ying ; Lin, Hsiao-Han ; Hsieh, Yin-Cheng ; Wang, Nan-Hsuan ; Kuo, Yin-Chieh ; Chu, Ping-Tzu ; Tung, Hsin-Yi ; Wu, Yi-Chen ; Sun, Juo-Ling ; Liu, Sheng-Yu ; Li, Wan-Fen ; Lee, Wei-Han ; Lai, Jiann-Shiun ; Chang, Michael ; Lai, Ming-Tain</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c623t-a621fc1eab287fb7a08edc041273b390984c9d3eec8111669917b282a0adf6e03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adjuvants, Immunologic</topic><topic>Adjuvants, Pharmaceutic</topic><topic>Aluminum</topic><topic>Aluminum hydroxide</topic><topic>Analysis</topic><topic>Animal experimentation</topic><topic>Animals</topic><topic>Animals, Laboratory</topic><topic>Antibodies, Neutralizing</topic><topic>Antibodies, Viral</topic><topic>Antigens</topic><topic>Biology and Life Sciences</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 Vaccines</topic><topic>Evaluation</topic><topic>Global economy</topic><topic>Humans</topic><topic>Immunity</topic><topic>Immunization</topic><topic>Immunogenicity</topic><topic>Immunoglobulin G</topic><topic>Infections</topic><topic>ISCOMS</topic><topic>Lymphocytes T</topic><topic>Medicine and Health Sciences</topic><topic>Molecular weight</topic><topic>Nanoparticles</topic><topic>Neutralization</topic><topic>Pandemics</topic><topic>Physical Sciences</topic><topic>Protein Subunits</topic><topic>Proteins</topic><topic>Research and Analysis Methods</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Spike Glycoprotein, Coronavirus - genetics</topic><topic>Spike protein</topic><topic>Vaccines</topic><topic>Viral diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, Ming-Chen</creatorcontrib><creatorcontrib>Wang, Chun-Chung</creatorcontrib><creatorcontrib>Tang, Wei-Chien</creatorcontrib><creatorcontrib>Chen, Kuan-Ming</creatorcontrib><creatorcontrib>Chen, Chu-Ying</creatorcontrib><creatorcontrib>Lin, Hsiao-Han</creatorcontrib><creatorcontrib>Hsieh, Yin-Cheng</creatorcontrib><creatorcontrib>Wang, Nan-Hsuan</creatorcontrib><creatorcontrib>Kuo, Yin-Chieh</creatorcontrib><creatorcontrib>Chu, Ping-Tzu</creatorcontrib><creatorcontrib>Tung, Hsin-Yi</creatorcontrib><creatorcontrib>Wu, Yi-Chen</creatorcontrib><creatorcontrib>Sun, Juo-Ling</creatorcontrib><creatorcontrib>Liu, Sheng-Yu</creatorcontrib><creatorcontrib>Li, Wan-Fen</creatorcontrib><creatorcontrib>Lee, Wei-Han</creatorcontrib><creatorcontrib>Lai, Jiann-Shiun</creatorcontrib><creatorcontrib>Chang, Michael</creatorcontrib><creatorcontrib>Lai, Ming-Tain</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, Ming-Chen</au><au>Wang, Chun-Chung</au><au>Tang, Wei-Chien</au><au>Chen, Kuan-Ming</au><au>Chen, Chu-Ying</au><au>Lin, Hsiao-Han</au><au>Hsieh, Yin-Cheng</au><au>Wang, Nan-Hsuan</au><au>Kuo, Yin-Chieh</au><au>Chu, Ping-Tzu</au><au>Tung, Hsin-Yi</au><au>Wu, Yi-Chen</au><au>Sun, Juo-Ling</au><au>Liu, Sheng-Yu</au><au>Li, Wan-Fen</au><au>Lee, Wei-Han</au><au>Lai, Jiann-Shiun</au><au>Chang, Michael</au><au>Lai, Ming-Tain</au><au>Ito, Etsuro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunogenicity of a spike protein subunit-based COVID-19 vaccine with broad protection against various SARS-CoV-2 variants in animal studies</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2023-03-24</date><risdate>2023</risdate><volume>18</volume><issue>3</issue><spage>e0283473</spage><epage>e0283473</epage><pages>e0283473-e0283473</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>SARS-CoV-2 pandemic has profound impacts on human life and global economy since the outbreak in 2019. With the new variants continue to emerge with greater immune escaping capability, the protectivity of the available vaccines is compromised. Therefore, development a vaccine that is capable of inducing immunity against variants including omicron strains is in urgent need. In this study, we developed a protein-based vaccine BCVax that is consisted of antigen delta strain spike protein and QS21-based adjuvant AB801 in nanoparticle immune stimulation complex format (AB801-ISCOM). Results from animal studies showed that high level of anti-S protein IgG was induced after two doses of BCVax and the IgG was capable of neutralizing multiple variants of pseudovirus including omicron BA.1 or BA.2 strains. In addition, strong Th1 response was stimulated after BCVax immunization. Furthermore, BCvax with AB801-ISCOM as the adjuvant showed significant stronger immunity compared with the vaccine using aluminum hydroxide plus CpG 1018 as the adjuvant. BCVax was also evaluated as a booster after two prior vaccinations, the IgG titers and pseudovirus neutralization activities against BA.2 or BA.4/BA.5 were further enhanced suggesting BCVax is a promising candidate as booster. Taken together, the pre-clinical data warrant BCVax for further development in clinic.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>36961826</pmid><doi>10.1371/journal.pone.0283473</doi><tpages>e0283473</tpages><orcidid>https://orcid.org/0000-0001-5330-6984</orcidid><orcidid>https://orcid.org/0000-0002-9829-7943</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2023-03, Vol.18 (3), p.e0283473-e0283473 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2790305497 |
| source | Public Library of Science (PLoS) Journals Open Access; MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Adjuvants, Immunologic Adjuvants, Pharmaceutic Aluminum Aluminum hydroxide Analysis Animal experimentation Animals Animals, Laboratory Antibodies, Neutralizing Antibodies, Viral Antigens Biology and Life Sciences Coronaviruses COVID-19 COVID-19 - prevention & control COVID-19 Vaccines Evaluation Global economy Humans Immunity Immunization Immunogenicity Immunoglobulin G Infections ISCOMS Lymphocytes T Medicine and Health Sciences Molecular weight Nanoparticles Neutralization Pandemics Physical Sciences Protein Subunits Proteins Research and Analysis Methods SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Spike Glycoprotein, Coronavirus - genetics Spike protein Vaccines Viral diseases |
| title | Immunogenicity of a spike protein subunit-based COVID-19 vaccine with broad protection against various SARS-CoV-2 variants in animal studies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T06%3A43%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunogenicity%20of%20a%20spike%20protein%20subunit-based%20COVID-19%20vaccine%20with%20broad%20protection%20against%20various%20SARS-CoV-2%20variants%20in%20animal%20studies&rft.jtitle=PloS%20one&rft.au=Yang,%20Ming-Chen&rft.date=2023-03-24&rft.volume=18&rft.issue=3&rft.spage=e0283473&rft.epage=e0283473&rft.pages=e0283473-e0283473&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0283473&rft_dat=%3Cgale_plos_%3EA742879681%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2790305497&rft_id=info:pmid/36961826&rft_galeid=A742879681&rft_doaj_id=oai_doaj_org_article_6fb17c9ac64c44429bdf1cbbdafd9f89&rfr_iscdi=true |